{"id":48646,"date":"2025-11-19T20:45:52","date_gmt":"2025-11-19T12:45:52","guid":{"rendered":"https:\/\/flcube.com\/?p=48646"},"modified":"2025-11-19T20:45:53","modified_gmt":"2025-11-19T12:45:53","slug":"mirxes-and-walvax-form-rna-partnership-for-vaccines-and-precision-medicine","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48646","title":{"rendered":"Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine"},"content":{"rendered":"\n<p><strong>Mirxes Holding Company Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2629:HKG\">HKG: 2629<\/a>) and <strong>Walvax Biotechnology Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/300142:SHE\">300142.SZ<\/a>) signed a <strong>Memorandum of Understanding (MOU)<\/strong> to establish a strategic partnership for creating an <strong>RNA\u2011centric platform<\/strong> focused on <strong>prophylaxis and precision medicine<\/strong>, covering co\u2011development, clinical trials, registration, and commercialization.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure\">Partnership Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Mirxes Holding (HKG: 2629) &amp; Walvax Biotechnology (SHE: 300142)<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Memorandum of Understanding (MOU)<\/td><\/tr><tr><td><strong>Platform Focus<\/strong><\/td><td>RNA\u2011centric platform for prophylaxis and precision medicine<\/td><\/tr><tr><td><strong>Scope<\/strong><\/td><td>Co\u2011development, clinical trials &amp; registration, sales &amp; distribution<\/td><\/tr><tr><td><strong>Geography<\/strong><\/td><td>China (initial focus)<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Definitive agreements expected Q1\u202f2026; first co\u2011developed program targeted for IND filing H2\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partner-profiles\">Partner Profiles<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-walvax-biotechnology\">Walvax Biotechnology<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded:<\/strong> 2001<\/li>\n\n\n\n<li><strong>Market Cap:<\/strong> \u00a545\u202fbillion (US$6.2\u202fbillion)<\/li>\n\n\n\n<li><strong>Technology Platforms:<\/strong> Bacterial vaccines, recombinant protein vaccines, <strong>mRNA vaccines<\/strong>, recombinant adenovirus vector vaccines<\/li>\n\n\n\n<li><strong>Commercial Portfolio:<\/strong> 8 vaccine varieties (14 specifications) launched; <strong>mRNA COVID\u201119 vaccine (Omicron XBB.1.5)<\/strong> approved for emergency use in December\u202f2023<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> GMP\u2011compliant facilities with annual capacity exceeding <strong>200\u202fmillion doses<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-mirxes-holding\">Mirxes Holding<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Listed:<\/strong> HKEX (HKG: 2629), market cap ~HK$8\u202fbillion (US$1.0\u202fbillion)<\/li>\n\n\n\n<li><strong>Focus:<\/strong> RNA technology, precision diagnostics, and therapeutic development<\/li>\n\n\n\n<li><strong>Strategic Rationale:<\/strong> Leverages Walvax\u2019s proven mRNA manufacturing and Mirxes\u2019s RNA R&amp;D to create integrated platform<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Synergy:<\/strong> Combine Walvax\u2019s <strong>mRNA vaccine expertise<\/strong> with Mirxes\u2019s <strong>precision medicine pipeline<\/strong> to develop next\u2011generation RNA therapeutics beyond infectious diseases.<\/li>\n\n\n\n<li><strong>Market Gap:<\/strong> No major Chinese biopharma offers an <strong>end\u2011to\u2011end RNA platform<\/strong> spanning discovery, manufacturing, and commercialization for both prophylactic vaccines and precision oncology therapies.<\/li>\n\n\n\n<li><strong>Regulatory Advantage:<\/strong> Walvax\u2019s established NMPA relationships and track record (COVID\u201119 mRNA approval) may accelerate clinical trial initiation and regulatory review.<\/li>\n\n\n\n<li><strong>Commercial Scale:<\/strong> Walvax\u2019s distribution network covers <strong>31 provinces<\/strong> and 2,000+ CDCs, providing immediate channel access for any co\u2011developed products.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Segment<\/th><th>China Market Size (2024)<\/th><th>Growth CAGR<\/th><th>RNA Platform Potential<\/th><\/tr><\/thead><tbody><tr><td><strong>Prophylactic mRNA Vaccines<\/strong><\/td><td>\u00a58.5\u202fbillion (US$1.2\u202fbillion)<\/td><td>25%<\/td><td>\u00a53.0\u202fbillion by 2030 (35% share)<\/td><\/tr><tr><td><strong>Precision Oncology RNA<\/strong><\/td><td>\u00a52.1\u202fbillion (US$290\u202fmillion)<\/td><td>40%<\/td><td>\u00a51.5\u202fbillion by 2030 (70% share)<\/td><\/tr><tr><td><strong>Total Addressable Market<\/strong><\/td><td>\u00a510.6\u202fbillion (US$1.5\u202fbillion)<\/td><td>29%<\/td><td>\u00a54.5\u202fbillion peak sales potential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Model:<\/strong> Co\u2011development costs split 50\/50; profits shared based on contribution (estimated <strong>60% Walvax \/ 40% Mirxes<\/strong> for vaccines, <strong>50\/50<\/strong> for precision medicine).<\/li>\n\n\n\n<li><strong>Pipeline Forecast:<\/strong> First <strong>mRNA cancer vaccine<\/strong> (KRAS\u2011mutated solid tumors) expected to enter clinic <strong>Q4\u202f2026<\/strong>; first <strong>infectious disease booster<\/strong> (influenza\/COVID combo) <strong>Q2\u202f2027<\/strong>.<\/li>\n\n\n\n<li><strong>Competitive Moat:<\/strong> Partnership creates <strong>China\u2019s only dual\u2011capability RNA platform<\/strong>, potentially deterring late\u2011stage entrants.<\/li>\n\n\n\n<li><strong>Valuation Impact:<\/strong> Mirxes shares rose <strong>8.3%<\/strong> on announcement; analysts see <strong>15\u201120% upside<\/strong> if definitive agreement includes upfront payment or profit\u2011share guarantees.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the Mirxes\u2011Walvax partnership, RNA platform development, and commercial potential. Actual results may differ materially due to risks including failure to finalize definitive agreements, clinical trial outcomes, regulatory approval timelines, and market competition.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025111800301_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025111800301_c.\"><\/object><a id=\"wp-block-file--media-3064efbd-0407-4f74-9f0f-36fb1617a068\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025111800301_c.pdf\">2025111800301_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025111800301_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-3064efbd-0407-4f74-9f0f-36fb1617a068\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mirxes Holding Company Limited (HKG: 2629) and Walvax Biotechnology Co., Ltd. (300142.SZ) signed a Memorandum&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48648,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4245,811,63,1152,12,332],"class_list":["post-48646","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hkg-2629","tag-mirxes","tag-mrna","tag-she-300142","tag-vaccine","tag-walvax-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Mirxes Holding Company Limited (HKG: 2629) and Walvax Biotechnology Co., Ltd. (300142.SZ) signed a Memorandum of Understanding (MOU) to establish a strategic partnership for creating an RNA\u2011centric platform focused on prophylaxis and precision medicine, covering co\u2011development, clinical trials, registration, and commercialization.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48646\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine\" \/>\n<meta property=\"og:description\" content=\"Mirxes Holding Company Limited (HKG: 2629) and Walvax Biotechnology Co., Ltd. (300142.SZ) signed a Memorandum of Understanding (MOU) to establish a strategic partnership for creating an RNA\u2011centric platform focused on prophylaxis and precision medicine, covering co\u2011development, clinical trials, registration, and commercialization.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48646\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-19T12:45:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-19T12:45:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1903.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48646#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48646\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine\",\"datePublished\":\"2025-11-19T12:45:52+00:00\",\"dateModified\":\"2025-11-19T12:45:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48646\"},\"wordCount\":457,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48646#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1903.webp\",\"keywords\":[\"HKG: 2629\",\"Mirxes\",\"mRNA\",\"SHE: 300142\",\"Vaccine\",\"Walvax Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48646#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48646\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48646\",\"name\":\"Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48646#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48646#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1903.webp\",\"datePublished\":\"2025-11-19T12:45:52+00:00\",\"dateModified\":\"2025-11-19T12:45:53+00:00\",\"description\":\"Mirxes Holding Company Limited (HKG: 2629) and Walvax Biotechnology Co., Ltd. (300142.SZ) signed a Memorandum of Understanding (MOU) to establish a strategic partnership for creating an RNA\u2011centric platform focused on prophylaxis and precision medicine, covering co\u2011development, clinical trials, registration, and commercialization.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48646#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48646\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48646#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1903.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1903.webp\",\"width\":1080,\"height\":608,\"caption\":\"Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48646#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine - Insight, China&#039;s Pharmaceutical Industry","description":"Mirxes Holding Company Limited (HKG: 2629) and Walvax Biotechnology Co., Ltd. (300142.SZ) signed a Memorandum of Understanding (MOU) to establish a strategic partnership for creating an RNA\u2011centric platform focused on prophylaxis and precision medicine, covering co\u2011development, clinical trials, registration, and commercialization.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48646","og_locale":"en_US","og_type":"article","og_title":"Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine","og_description":"Mirxes Holding Company Limited (HKG: 2629) and Walvax Biotechnology Co., Ltd. (300142.SZ) signed a Memorandum of Understanding (MOU) to establish a strategic partnership for creating an RNA\u2011centric platform focused on prophylaxis and precision medicine, covering co\u2011development, clinical trials, registration, and commercialization.","og_url":"https:\/\/flcube.com\/?p=48646","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-19T12:45:52+00:00","article_modified_time":"2025-11-19T12:45:53+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1903.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48646#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48646"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine","datePublished":"2025-11-19T12:45:52+00:00","dateModified":"2025-11-19T12:45:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48646"},"wordCount":457,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48646#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1903.webp","keywords":["HKG: 2629","Mirxes","mRNA","SHE: 300142","Vaccine","Walvax Biotechnology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48646#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48646","url":"https:\/\/flcube.com\/?p=48646","name":"Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48646#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48646#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1903.webp","datePublished":"2025-11-19T12:45:52+00:00","dateModified":"2025-11-19T12:45:53+00:00","description":"Mirxes Holding Company Limited (HKG: 2629) and Walvax Biotechnology Co., Ltd. (300142.SZ) signed a Memorandum of Understanding (MOU) to establish a strategic partnership for creating an RNA\u2011centric platform focused on prophylaxis and precision medicine, covering co\u2011development, clinical trials, registration, and commercialization.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48646#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48646"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48646#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1903.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1903.webp","width":1080,"height":608,"caption":"Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48646#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1903.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48646"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48646\/revisions"}],"predecessor-version":[{"id":48649,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48646\/revisions\/48649"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48648"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}